Loading...
•
Sep 30, 2020
Guardant Health Q3 2020 Earnings Report
Reported a 23% increase in revenue compared to the prior year period.
Key Takeaways
Guardant Health reported a strong third quarter with a 23% increase in revenue compared to the corresponding period of 2019. The company also received FDA approval for Guardant360® CDx and launched an enhanced version of Guardant360.
Revenue of $74.6 million for the third quarter of 2020, an increase of 23% over the corresponding period of 2019
Precision oncology revenue of $60.4 million, an increase of 16% over the corresponding period of 2019
Reported 16,950 tests to clinical customers and 3,071 tests to biopharmaceutical customers in the third quarter of 2020, representing an increase of 28% and a decrease of 42%, respectively, over the third quarter of 2019
Received FDA-approval for Guardant360® CDx, becoming the first liquid biopsy test for comprehensive tumor mutation profiling across all solid cancers
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.